Daniele Focosi (D Focosi)

Scopus Author ID Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 139

Top Venues

Viruses

Life (Basel, Switzerland)

Transfusion

International journal of molecular sciences

Azienda Ospedaliero-Universitaria Pisana

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Azienda Ospedaliero-Universitaria Pisana May 12 2012

Italy

Staff physician :: North-Western Tuscany Blood Bank

Publications

Daniele Focosi, Pietro Giorgio Spezia, Fabrizio Maggi
Subsequent Waves of Convergent Evolution in SARS-CoV-2 Genes and Proteins. Vaccines 12 (8) (2024)
Daniele Focosi, Arturo Casadevall, Massimo Franchini, Fabrizio Maggi
Sotrovimab: A Review of Its Efficacy against SARS-CoV-2 Variants. Viruses 16 (2) (2024)
Massimo Franchini, Daniele Focosi
Hyperimmune Plasma and Immunoglobulins against COVID-19: A Narrative Review. Life (Basel, Switzerland) 14 (2) (2024)
Cesare Ernesto Maria Gruber, Fabio Giovanni Tucci, Emanuela Giombini, Valentina Mazzotta, Pietro Giorgio Spezia, Martina Reuca, Ilaria Mastrorosa, Lavinia Fabeni, Giulia Berno, Ornella Butera, Silvia Rosati, Eliana Specchiarello, Fabrizio Carletti, Daniele Focosi, Emanuele Nicastri, Enrico Girardi, Andrea Antinori, Fabrizio Maggi
Molnupiravir increases SARS-CoV-2 genome diversity and complexity: A case-control cohort study. Journal of medical virology 96 (5) (2024)
Daniele Focosi, Pietro Giorgio Spezia, Fabrizio Maggi
Online dashboards for SARS-CoV-2 wastewater-based epidemiology. Future microbiology 19 (9) (2024)
Daniele Focosi, Fabrizio Maggi
Avian Influenza Virus A(H5Nx) and Prepandemic Candidate Vaccines: State of the Art. International journal of molecular sciences 25 (15) (2024)
Daniele Focosi, Fabrizio Maggi
Avian Influenza Virus A(H5Nx) and Prepandemic Candidate Vaccines: State of the Art. International journal of molecular sciences 25 (15) (2024)
Daniele Focosi, Pietro Giorgio Spezia, Fabrizio Maggi
The Emerging Tool of the Human Anellovirome. Viruses 16 (6) (2024)
Pietro Giorgio Spezia, Fabrizio Carletti, Federica Novazzi, Eliana Specchiarello, Angelo Genoni, Francesca Drago Ferrante, Claudia Minosse, Giulia Matusali, Nicasio Mancini, Daniele Focosi, Guido Antonelli, Enrico Girardi, Fabrizio Maggi
Torquetenovirus Viremia Quantification Using Real-Time PCR Developed on a Fully Automated, Random-Access Platform. Viruses 16 (6) (2024)
Daniele Focosi, Arturo Casadevall, Massimo Franchini, Fabrizio Maggi
Sotrovimab: A Review of Its Efficacy against SARS-CoV-2 Variants. Viruses 16 (2) (2024)
Daniele Focosi, Massimo Franchini, Fabrizio Maggi, Shmuel Shoham
COVID-19 therapeutics. Clinical microbiology reviews 37 (2) (2024)
Maria Beatrice Valli, Maria Letizia Schiavone, Martina Rueca, Giulia Berno, Pietro Giorgio Spezia, Cesare Ernesto Maria Gruber, Federica Forbici, Lavinia Fabeni, Daniele Focosi, Enrico Girardi, Marcello Meledandri, Fabrizio Maggi
Partial N-gene target failure in the Seegene Allplex SARS-CoV-2 Master Assay as a proxy of SARS-CoV-2 BA.2.86. Microbiology spectrum (2024)
Massimo Franchini, Carlo Mengoli, Arturo Casadevall, Daniele Focosi
Exploring Study Design Foibles in Randomized Controlled Trials on Convalescent Plasma in Hospitalized COVID-19 Patients. Life (Basel, Switzerland) 14 (7) (2024)
Massimo Franchini, Daniele Focosi, Mario Cruciani, Michael J Joyner, Liise-Anne Pirofski, Jonathon W Senefeld, Shmuel Shoham, David J Sullivan, Arturo Casadevall
Safety and Efficacy of Convalescent Plasma Combined with Other Pharmaceutical Agents for Treatment of COVID-19 in Hospitalized Patients: A Systematic Review and Meta-Analysis. Diseases (Basel, Switzerland) 12 (3) (2024)
Daniele Focosi, Arturo Casadevall, Massimo Franchini, Fabrizio Maggi
Sotrovimab: A Review of Its Efficacy against SARS-CoV-2 Variants. Viruses 16 (2) (2024)
Daniele Focosi, Massimo Franchini, Jonathon W Senefeld, Michael J Joyner, David J Sullivan, Andrew Pekosz, Fabrizio Maggi, Arturo Casadevall
Passive immunotherapies for the next influenza pandemic. Reviews in medical virology 34 (3) (2024)
Massimo Franchini, Daniele Focosi
Hyperimmune Plasma and Immunoglobulins against COVID-19: A Narrative Review. Life (Basel, Switzerland) 14 (2) (2024)
Massimo Franchini, Carlo Mengoli, Arturo Casadevall, Daniele Focosi
Exploring Study Design Foibles in Randomized Controlled Trials on Convalescent Plasma in Hospitalized COVID-19 Patients. Life (Basel, Switzerland) 14 (7) (2024)
Massimo Franchini, Carlo Mengoli, Arturo Casadevall, Daniele Focosi
Exploring Study Design Foibles in Randomized Controlled Trials on Convalescent Plasma in Hospitalized COVID-19 Patients. Life (Basel, Switzerland) 14 (7) (2024)
Maria Beatrice Valli, Maria Letizia Schiavone, Martina Rueca, Giulia Berno, Pietro Giorgio Spezia, Cesare Ernesto Maria Gruber, Federica Forbici, Lavinia Fabeni, Daniele Focosi, Enrico Girardi, Marcello Meledandri, Fabrizio Maggi
Partial N-gene target failure in the Seegene Allplex SARS-CoV-2 Master Assay as a proxy of SARS-CoV-2 BA.2.86. Microbiology spectrum 12 (6) (2024)
Daniele Focosi, Arturo Casadevall, Massimo Franchini, Fabrizio Maggi
Sotrovimab: A Review of Its Efficacy against SARS-CoV-2 Variants. Viruses 16 (2) (2024)
Daniele Focosi, Massimo Franchini, Fabrizio Maggi, Shmuel Shoham
COVID-19 therapeutics. Clinical microbiology reviews 37 (2) (2024)
Maria Beatrice Valli, Maria Letizia Schiavone, Martina Rueca, Giulia Berno, Pietro Giorgio Spezia, Cesare Ernesto Maria Gruber, Federica Forbici, Lavinia Fabeni, Daniele Focosi, Enrico Girardi, Marcello Meledandri, Fabrizio Maggi
Partial N-gene target failure in the Seegene Allplex SARS-CoV-2 Master Assay as a proxy of SARS-CoV-2 BA.2.86. Microbiology spectrum 12 (6) (2024)
Daniele Focosi, Pietro Giorgio Spezia, Fabrizio Maggi
The Emerging Tool of the Human Anellovirome. Viruses 16 (6) (2024)
Daniele Focosi, Pietro Giorgio Spezia, Fabrizio Maggi
Online dashboards for SARS-CoV-2 wastewater-based epidemiology. Future microbiology 19 (9) (2024)
Massimo Franchini, Daniele Focosi, Mario Cruciani, Michael J Joyner, Liise-Anne Pirofski, Jonathon W Senefeld, Shmuel Shoham, David J Sullivan, Arturo Casadevall
Safety and Efficacy of Convalescent Plasma Combined with Other Pharmaceutical Agents for Treatment of COVID-19 in Hospitalized Patients: A Systematic Review and Meta-Analysis. Diseases (Basel, Switzerland) 12 (3) (2024)
Massimo Franchini, Daniele Focosi, Mario Cruciani, Michael J Joyner, Liise-Anne Pirofski, Jonathon W Senefeld, Shmuel Shoham, David J Sullivan, Arturo Casadevall
Safety and Efficacy of Convalescent Plasma Combined with Other Pharmaceutical Agents for Treatment of COVID-19 in Hospitalized Patients: A Systematic Review and Meta-Analysis. Diseases (Basel, Switzerland) 12 (3) (2024)
Daniele Focosi, Pietro Giorgio Spezia, Fabrizio Maggi
The Emerging Tool of the Human Anellovirome. Viruses 16 (6) (2024)
Pietro Giorgio Spezia, Fabrizio Carletti, Federica Novazzi, Eliana Specchiarello, Angelo Genoni, Francesca Drago Ferrante, Claudia Minosse, Giulia Matusali, Nicasio Mancini, Daniele Focosi, Guido Antonelli, Enrico Girardi, Fabrizio Maggi
Torquetenovirus Viremia Quantification Using Real-Time PCR Developed on a Fully Automated, Random-Access Platform. Viruses 16 (6) (2024)
Daniele Focosi, Massimo Franchini, Fabrizio Maggi, Shmuel Shoham
COVID-19 therapeutics. Clinical microbiology reviews 37 (2) (2024)
Giulia Matusali, Valentina Mazzotta, Silvia Meschi, Francesca Colavita, Roberta Gagliardini, Aurora Bettini, Cesare Ernesto Maria Gruber, Alessandra Vergori, Paola Gallì, Daniele Focosi, Enrico Girardi, Andrea Antinori, Fabrizio Maggi
JN.1 neutralizing antibody titers after XBB.1.5 monovalent vaccine boost in healthcare workers and people with HIV. Journal of medical virology 96 (5) (2024)
Maria Beatrice Valli, Maria Letizia Schiavone, Martina Rueca, Giulia Berno, Pietro Giorgio Spezia, Cesare Ernesto Maria Gruber, Federica Forbici, Lavinia Fabeni, Daniele Focosi, Enrico Girardi, Marcello Meledandri, Fabrizio Maggi
Partial N-gene target failure in the Seegene Allplex SARS-CoV-2 Master Assay as a proxy of SARS-CoV-2 BA.2.86. Microbiology spectrum 12 (6) (2024)
Daniele Focosi, Massimo Franchini, Fabrizio Maggi, Shmuel Shoham
COVID-19 therapeutics. Clinical microbiology reviews 37 (2) (2024)
Silvia Meschi, Francesca Colavita, Giulia Matusali, Daniele Focosi, Fabrizio Maggi, Massimo Franchini
Incidentally detected West Nile virus-RNA positive blood donors do not harbor high titers of neutralizing antibodies. Transfusion 64 (8) (2024)
Daniele Focosi, Massimo Franchini, Fabrizio Maggi, Shmuel Shoham
COVID-19 therapeutics. Clinical microbiology reviews (2024)
Daniele Focosi, Pietro Giorgio Spezia, Fabrizio Maggi
Online dashboards for SARS-CoV-2 wastewater-based epidemiology. Future microbiology (2024)
Daniele Focosi, Pietro Giorgio Spezia, Fabrizio Maggi
Online dashboards for SARS-CoV-2 wastewater-based epidemiology. Future microbiology 19 (9) (2024)
Pietro Giorgio Spezia, Fabrizio Carletti, Federica Novazzi, Eliana Specchiarello, Angelo Genoni, Francesca Drago Ferrante, Claudia Minosse, Giulia Matusali, Nicasio Mancini, Daniele Focosi, Guido Antonelli, Enrico Girardi, Fabrizio Maggi
Torquetenovirus Viremia Quantification Using Real-Time PCR Developed on a Fully Automated, Random-Access Platform. Viruses 16 (6) (2024)
Massimo Franchini, Mario Cruciani, Arturo Casadevall, Michael J Joyner, Jonathon W Senefeld, David J Sullivan, Matteo Zani, Daniele Focosi
Safety of COVID-19 convalescent plasma: A definitive systematic review and meta-analysis of randomized controlled trials. Transfusion 64 (2) (2023)
Daniele Focosi, Fabrizio Maggi
Second-Generation SARS-CoV-2 Recombinants: Lessons from Other Viruses. Viruses 15 (5) (2023)
Massimo Franchini, Arturo Casadevall, Michael J Joyner, Daniele Focosi
WHO Is Recommending against the Use of COVID-19 Convalescent Plasma in Immunocompromised Patients? Life (Basel, Switzerland) 13 (1) (2023)
Daniele Focosi, Rodrigo Quiroga, Scott A McConnell, Marc C Johnson, Arturo Casadevall
Convergent Evolution in SARS-CoV-2 Spike Creates a Variant Soup from Which New COVID-19 Waves Emerge. International journal of molecular sciences 24 (3) (2023)
David J Sullivan, Massimo Franchini, Jonathon W Senefeld, Michael J Joyner, Arturo Casadevall, Daniele Focosi
Outpatient Treatment of Confirmed COVID-19. Annals of internal medicine (2023)
Massimo Franchini, Daniele Focosi
The Role of Convalescent Plasma in COVID-19: A Conclusive Post-Pandemic Review. Life (Basel, Switzerland) 13 (12) (2023)
Daniele Focosi, Rodrigo Quiroga, Scott A McConnell, Marc C Johnson, Arturo Casadevall
Convergent Evolution in SARS-CoV-2 Spike Creates a Variant Soup from Which New COVID-19 Waves Emerge. International journal of molecular sciences 24 (3) (2023)
Daniele Focosi
From Co-Administration to Co-Formulation: The Race for New Vaccines against COVID-19 and Other Respiratory Viruses. Vaccines 11 (1) (2023)
Daniele Focosi, Pietro Giorgio Spezia, Fabrizio Maggi
SARS-CoV-2 BA.2.86 ("Pirola"): Is it Pi or Just Another Omicron Sublineage? Vaccines 11 (11) (2023)
Arturo Casadevall, Michael J Joyner, Liise-Anne Pirofski, Jonathon W Senefeld, Shmuel Shoham, David Sullivan, Nigel Paneth, Daniele Focosi
Convalescent plasma therapy in COVID-19: Unravelling the data using the principles of antibody therapy. Expert review of respiratory medicine (2023)
Daniele Focosi, Fabrizio Maggi
How SARS-CoV-2 Big Data Are Challenging Viral Taxonomy Rules. Viruses 15 (3) (2023)
Daniele Focosi
A Web Tool to Estimate Baseline Anti-Spike Monoclonal Antibody Efficacy Based on Regional Genomic Surveillance. Viruses 15 (5) (2023)
Massimo Franchini, Mario Cruciani, Arturo Casadevall, Michael J Joyner, Jonathon W Senefeld, David J Sullivan, Matteo Zani, Daniele Focosi
Safety of COVID-19 convalescent plasma: A definitive systematic review and meta-analysis of randomized controlled trials. Transfusion 64 (2) (2023)
Daniele Focosi, Fabrizio Maggi
How SARS-CoV-2 Big Data Are Challenging Viral Taxonomy Rules. Viruses 15 (3) (2023)
Daniele Focosi
From Co-Administration to Co-Formulation: The Race for New Vaccines against COVID-19 and Other Respiratory Viruses. Vaccines 11 (1) (2023)
Daniele Focosi, Pietro Giorgio Spezia, Anna-Lisa Capria, Federico Gueli, Scott A McConnell, Federica Novazzi, Mauro Pistello
Rise of the BQ.1.1.37 SARS-CoV-2 Sublineage, Italy. Diagnostics (Basel, Switzerland) 13 (5) (2023)
David J Sullivan, Daniele Focosi, Daniel F Hanley, Mario Cruciani, Massimo Franchini, Jiangda Ou, Arturo Casadevall, Nigel Paneth
Outpatient randomized controlled trials to reduce COVID-19 hospitalization: Systematic review and meta-analysis. Journal of medical virology 95 (12) (2023)
Massimo Franchini, Marco Zaffanello, Daniele Focosi
Current factor IX replacement options for hemophilia B and the challenges ahead. Expert opinion on pharmacotherapy (2023)
Daniele Focosi
From Co-Administration to Co-Formulation: The Race for New Vaccines against COVID-19 and Other Respiratory Viruses. Vaccines 11 (1) (2023)
Daniele Focosi, Fabrizio Maggi
SARS-CoV-2: Advances in Serological Methods and the Understanding of Antibody Escape. International journal of molecular sciences 24 (3) (2023)
Daniele Focosi, Rodrigo Quiroga, Scott A McConnell, Marc C Johnson, Arturo Casadevall
Convergent Evolution in SARS-CoV-2 Spike Creates a Variant Soup from Which New COVID-19 Waves Emerge. International journal of molecular sciences 24 (3) (2023)
Daniele Focosi, Pietro Giorgio Spezia, Anna-Lisa Capria, Federico Gueli, Scott A McConnell, Federica Novazzi, Mauro Pistello
Rise of the BQ.1.1.37 SARS-CoV-2 Sublineage, Italy. Diagnostics (Basel, Switzerland) 13 (5) (2023)
Massimo Franchini, Mario Cruciani, Arturo Casadevall, Michael J Joyner, Jonathon W Senefeld, David J Sullivan, Matteo Zani, Daniele Focosi
Safety of COVID-19 convalescent plasma: A definitive systematic review and meta-analysis of randomized controlled trials. Transfusion (2023)
Massimo Franchini, Mario Cruciani, Arturo Casadevall, Michael J Joyner, Jonathon W Senefeld, David J Sullivan, Matteo Zani, Daniele Focosi
Safety of COVID-19 convalescent plasma: A definitive systematic review and meta-analysis of randomized controlled trials. Transfusion 64 (2) (2023)
Daniele Focosi, Fabrizio Maggi
Respiratory delivery of passive immunotherapies for SARS-CoV-2 prophylaxis and therapy. Human vaccines & immunotherapeutics 19 (2) (2023)
Daniele Focosi, Emanuele Nicastri
Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Hospitalized Patients With COVID-19. Annals of internal medicine 176 (10) (2023)
David J Sullivan, Daniele Focosi, Daniel F Hanley, Mario Cruciani, Massimo Franchini, Jiangda Ou, Arturo Casadevall, Nigel Paneth
Outpatient randomized controlled trials to reduce COVID-19 hospitalization: Systematic review and meta-analysis. Journal of medical virology 95 (12) (2023)
Daniele Focosi, Fabrizio Maggi
How SARS-CoV-2 Big Data Are Challenging Viral Taxonomy Rules. Viruses 15 (3) (2023)
Daniele Focosi, Pietro Giorgio Spezia, Federico Gueli, Fabrizio Maggi
The Era of the FLips: How Spike Mutations L455F and F456L (and A475V) Are Shaping SARS-CoV-2 Evolution. Viruses 16 (1) (2023)
Massimo Franchini, Mario Cruciani, Arturo Casadevall, Michael J Joyner, Jonathon W Senefeld, David J Sullivan, Matteo Zani, Daniele Focosi
Safety of COVID-19 convalescent plasma: A definitive systematic review and meta-analysis of randomized controlled trials. Transfusion 64 (2) (2023)
Daniele Focosi, Pietro Giorgio Spezia, Federico Gueli, Fabrizio Maggi
The Era of the FLips: How Spike Mutations L455F and F456L (and A475V) Are Shaping SARS-CoV-2 Evolution. Viruses 16 (1) (2023)
Daniele Focosi, Massimo Franchini
COVID-19 convalescent plasma retains value for immunocompromised patients. Leukemia (2023)
Daniele Focosi, Fabrizio Maggi
SARS-CoV-2: Advances in Serological Methods and the Understanding of Antibody Escape. International journal of molecular sciences 24 (3) (2023)
Daniele Focosi, Rodrigo Quiroga, Scott A McConnell, Marc C Johnson, Arturo Casadevall
Convergent Evolution in SARS-CoV-2 Spike Creates a Variant Soup from Which New COVID-19 Waves Emerge. International journal of molecular sciences 24 (3) (2023)
Daniele Focosi, Pietro Giorgio Spezia, Federico Gueli, Fabrizio Maggi
The Era of the FLips: How Spike Mutations L455F and F456L (and A475V) Are Shaping SARS-CoV-2 Evolution. Viruses 16 (1) (2023)
David J Sullivan, Daniele Focosi, Daniel F Hanley, Mario Cruciani, Massimo Franchini, Jiangda Ou, Arturo Casadevall, Nigel Paneth
Outpatient randomized controlled trials to reduce COVID-19 hospitalization: Systematic review and meta-analysis. Journal of medical virology 95 (12) (2023)
Massimo Franchini, Mario Cruciani, Arturo Casadevall, Michael J Joyner, Jonathon W Senefeld, David J Sullivan, Matteo Zani, Daniele Focosi
Safety of COVID-19 convalescent plasma: A definitive systematic review and meta-analysis of randomized controlled trials. Transfusion (2023)
Daniele Focosi, Massimo Franchini, Emanuele Nicastri, David J Sullivan, Arturo Casadevall
Convalescent Plasma Versus Hyperimmune Immunoglobulins. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023)
Massimo Franchini, Mario Cruciani, Arturo Casadevall, Michael J Joyner, Jonathon W Senefeld, David J Sullivan, Matteo Zani, Daniele Focosi
Safety of COVID-19 convalescent plasma: A definitive systematic review and meta-analysis of randomized controlled trials. Transfusion 64 (2) (2023)
Claudia Minosse, Giulia Matusali, Silvia Meschi, Germana Grassi, Massimo Francalancia, Gianpiero D'Offizi, Pietro Giorgio Spezia, Anna Rosa Garbuglia, Marzia Montalbano, Daniele Focosi, Enrico Girardi, Francesco Vaia, Giuseppe Maria Ettorre, Fabrizio Maggi
Torquetenovirus Loads in Peripheral Blood Predict Both the Humoral and Cell-Mediated Responses to SARS-CoV-2 Elicited by the mRNA Vaccine in Liver Transplant Recipients. Vaccines 11 (11) (2023)
Daniele Focosi, Fabrizio Maggi
SARS-CoV-2: Advances in Serological Methods and the Understanding of Antibody Escape. International journal of molecular sciences 24 (3) (2023)
Massimo Franchini, Mario Cruciani, Arturo Casadevall, Michael J Joyner, Jonathon W Senefeld, David J Sullivan, Matteo Zani, Daniele Focosi
Safety of COVID-19 convalescent plasma: A definitive systematic review and meta-analysis of randomized controlled trials. Transfusion 64 (2) (2023)
Massimo Franchini, Arturo Casadevall, Michael J Joyner, Daniele Focosi
WHO Is Recommending against the Use of COVID-19 Convalescent Plasma in Immunocompromised Patients? Life (Basel, Switzerland) 13 (1) (2023)
David J Sullivan, Daniele Focosi, Daniel F Hanley, Mario Cruciani, Massimo Franchini, Jiangda Ou, Arturo Casadevall, Nigel Paneth
Outpatient randomized controlled trials to reduce COVID-19 hospitalization: Systematic review and meta-analysis. Journal of medical virology 95 (12) (2023)
Massimo Franchini, Daniele Focosi
The Role of Convalescent Plasma in COVID-19: A Conclusive Post-Pandemic Review. Life (Basel, Switzerland) 13 (12) (2023)
Massimo Franchini, Arturo Casadevall, Michael J Joyner, Daniele Focosi
WHO Is Recommending against the Use of COVID-19 Convalescent Plasma in Immunocompromised Patients? Life (Basel, Switzerland) 13 (1) (2023)
Massimo Franchini, Arturo Casadevall, Michael J Joyner, Daniele Focosi
WHO Is Recommending against the Use of COVID-19 Convalescent Plasma in Immunocompromised Patients? Life (Basel, Switzerland) 13 (1) (2023)
Francesca Romana Mauro, Andrea Visentin, Diana Giannarelli, Maria C Molinari, Giulia Proietti, Marco Petrella, Francesco Angotzi, Sara Pepe, Livio Trentin, Silvia Baroncelli, Emanuela Giombini, Silvia Meschi, Fabrizio Maggi, Daniele Focosi
Pre-exposure prophylaxis with tixagevimab/cilgavimab in patients with chronic lymphocytic leukaemia treated with targeted agents. British journal of haematology (2023)
Daniele Focosi, Pietro Giorgio Spezia, Federico Gueli, Fabrizio Maggi
The Era of the FLips: How Spike Mutations L455F and F456L (and A475V) Are Shaping SARS-CoV-2 Evolution. Viruses 16 (1) (2023)
Massimo Franchini, Mario Cruciani, Arturo Casadevall, Michael J Joyner, Jonathon W Senefeld, David J Sullivan, Matteo Zani, Daniele Focosi
Safety of COVID-19 convalescent plasma: A definitive systematic review and meta-analysis of randomized controlled trials. Transfusion 64 (2) (2023)
Daniele Focosi, Arturo Casadevall
A Critical Analysis of the Use of Cilgavimab plus Tixagevimab Monoclonal Antibody Cocktail (Evusheld™) for COVID-19 Prophylaxis and Treatment. Viruses 14 (9) (2022)
Giovanni Belcari, Alberto Conti, Alessandro Mazzoni, Maria Lanza, Paola Mazzetti, Daniele Focosi
Clinical and Virological Response to Convalescent Plasma in a Chronic Lymphocytic Leukemia Patient with COVID-19 Pneumonia. Life (Basel, Switzerland) 12 (7) (2022)
Pietro Giorgio Spezia, Andreina Baj, Francesca Drago Ferrante, Sara Boutahar, Lorenzo Azzi, Angelo Genoni, Daniela Dalla Gasperina, Federica Novazzi, Francesco Dentali, Daniele Focosi, Fabrizio Maggi
Detection of Torquetenovirus and Redondovirus DNA in Saliva Samples from SARS-CoV-2-Positive and -Negative Subjects. Viruses 14 (11) (2022)
Daniele Focosi, Fabrizio Maggi
Do We Really Need Omicron Spike-Based Updated COVID-19 Vaccines? Evidence and Pipeline. Viruses 14 (11) (2022)
Daniele Focosi, Massimo Franchini, Michael J Joyner, Arturo Casadevall
Are convalescent plasma stocks collected during former COVID-19 waves still effective against current SARS-CoV-2 variants? Vox sanguinis 117 (5) (2022)
Daniele Focosi, Arturo Casadevall
Pathogen reduction technologies need to evaluate Fc-mediated antibody functions. Transfusion 62 (8) (2022)
Daniele Focosi, Fabrizio Maggi, Arturo Casadevall
Mucosal Vaccines, Sterilizing Immunity, and the Future of SARS-CoV-2 Virulence. Viruses 14 (2) (2022)
Daniele Focosi, Massimo Franchini, Fabrizio Maggi
Modified Hemagglutination Tests for COVID-19 Serology in Resource-Poor Settings: Ready for Prime-Time? Vaccines 10 (3) (2022)
Daniele Focosi, Fabrizio Maggi
Recombination in Coronaviruses, with a Focus on SARS-CoV-2. Viruses 14 (6) (2022)
Marco Tuccori, Irma Convertino, Sara Ferraro, Emiliano Cappello, Giulia Valdiserra, Giulia de Luca, Massimo Franchini, Daniele Focosi
Preclinical discovery and development of the casirivimab + imdevimab cocktail for the treatment of novel coronavirus infection: the rise and fall. Expert opinion on drug discovery 17 (6) (2022)
Daniele Focosi, Massimo Franchini, Marco Tuccori, Mario Cruciani
Efficacy of High-Dose Polyclonal Intravenous Immunoglobulin in COVID-19: A Systematic Review. Vaccines 10 (1) (2022)
Daniele Focosi, Massimo Franchini
Antibodies and SARS-CoV-2: New Data on Diagnostics and Therapeutics. Life (Basel, Switzerland) 12 (5) (2022)

Daniele Focosi.css-eqlu8i{font-size:small;padding-left:4px;} (D Focosi)

Publication Activity (10 Years)

Top Topics

Top Venues

Daniele Focosi (D Focosi)